Cutler Group’s CytomX Therapeutics CTMX Stock Holding History

Cutler Group’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,600	Closed	-$4K	–	4179
2018 Q2	$4K	Sell	10,600 -100	-0.9%	-$2.55K	﹤0.01%	3211
2018 Q1	$28K	Buy	+10,700	New	+$305K	﹤0.01%	2041

Other funds holding CTMX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cutler Group's CTMX Position: Q1 2024 in Review

Cutler Group sold out of CytomX Therapeutics (CTMX) in Q1 2024, closing a stake of 1,000 shares — an estimated $1K sold.

Cutler Group first reported a position in CTMX in Q4 2017 and held it in 23 quarters. The position peaked at $15K in Q4 2018. 88 funds tracked by Wall St. Rank hold CTMX as of Q1 2024.

Cutler Group reported no remaining CytomX Therapeutics position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 1,000 CytomX Therapeutics shares in Q1 2024, an estimated $1K.
Cutler Group first reported a position in CytomX Therapeutics in Q4 2017 and held it in 23 quarters.
Cutler Group's CytomX Therapeutics position peaked at $15K in Q4 2018.
88 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.